Gastric cancer (GC) is a major health concern globally, ranking fifth in frequency and fourth
in cancer-associated mortality 1. In China, an estimated 396,500 new cases are diagnosed …

Identification of the importance of human epidermal growth factor receptor-2 (HER2) status,
biomarker testing and the development of anti-HER2 treatments have changed the …

Background: The treatment of patients with advanced gastric cancer remains a most
challenging task in the clinical practice. Recently, targeted therapies have significantly …

We read with great interest the manuscript written by Makiyama et al [1]. In this paper, the
authors reported outcome results of the randomized phase II study WJOG7112G (T-ACT …

Worldwide, gastric cancer is the fifth common cancer type and causes the third most cancer-
associated deaths (1), mostly due to its commonly fatal outcome especially in locally …

Simple Summary Human epidermal receptor (HER) 2-positive advanced gastric cancer
(AGC) is one of the major subtypes of gastric cancer, accounting for~ 20% of all cases. After …

Gastric cancer (GC) is the fifth most common cancer worldwide. Despite recent
improvements in treatment quality and options, advanced gastric cancer remains one of the …

The prognostic value of human epidermal growth factor receptor 2 (HER2) in gastric cancer
is controversial. Consensus guidelines have standardized the testing of HER2 status in …

Gastric cancer is a biologically heterogeneous tumor. The identification of human epidermal
growth factor receptor-2 (HER2) biomarker overexpression in gastric cancer represented a …

Gastric cancer is one of the most common malignancy worldwide with a prognosis less than
1 year in unresectable or metastatic disease. HER2 expression is the main biomarker to …